High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
about
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerQuantification of HER family receptors in breast cancerProspective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerThe Therapeutic Challenge of Targeting HER2 in Endometrial CancerHER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyTherapeutic siRNA for drug-resistant HER2-positive breast cancer.Multi-omics approach to infer cancer therapeutic targets on chromosome 20q across tumor types.Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.HER2-positive breast cancer is lost in translation: time for patient-centered research.Perspectives of HER2-targeting in gastric and esophageal cancer.Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies.Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: A report of two instructive cases.Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.
P2860
Q26785612-C34DEFD8-3B48-4CD5-AF93-6CF390162AC6Q27015506-CA67E449-8CA7-4C88-95F2-87B8DF57A1B0Q36064908-5AFD675A-5554-4644-B5D3-B833F06EEE9FQ36064912-D99635AF-BAC0-4BBD-A263-1510CDC95B6EQ36087126-0B2BBA77-AD36-40DD-A3EB-FB16AA43AF13Q36107363-07C6C2E0-594C-450B-AF28-7CFA83809FDBQ36280470-80743776-085C-419E-838E-14D71DF5CE54Q36288976-C6825482-B951-4E5D-977B-7220CCFAC4DBQ37046699-467964F6-9912-4DD5-8557-8138B2C0DE7FQ37259845-022362A8-DD0C-47A4-B1DE-5AE92704478AQ38384113-1872F3E8-2C96-497F-AF95-E11FE6D86D12Q38387030-D83E361F-29AD-4A9D-90C0-B7219776B099Q38648765-D6F38B73-37D8-45FA-8543-03E8BCF775D9Q38848389-CFCF0AEA-1670-4BDB-8EE6-D1B41E11AD58Q47111722-46A785F0-070B-483B-9E4B-CE1A68070AC7Q47859326-6B31E425-17D2-409F-8F32-A16F3B51D3B2Q50037194-C29435FB-5869-4FA7-B2C6-EDB1C4307879Q51091805-1F9D12A8-271A-4443-A589-3F7BD35C67DDQ51195482-D601E364-B91C-4AF3-A3AC-21CE058DBD95Q51663342-E93ADBB5-B85B-4D55-8AD5-D0C3971DC8AFQ53518615-6DA6899F-7CAB-46ED-A290-AAECE3F9ACE2Q54187441-00F66442-A8FF-47B4-AD77-95B63AA08225
P2860
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
High HER2 expression correlate ...... of lapatinib and trastuzumab.
@en
type
label
High HER2 expression correlate ...... of lapatinib and trastuzumab.
@en
prefLabel
High HER2 expression correlate ...... of lapatinib and trastuzumab.
@en
P2093
P50
P1476
High HER2 expression correlate ...... n of lapatinib and trastuzumab
@en
P2093
Ahmed Chenna
Catherine Ellis
Christine Campbell
Claudia Aura
Dominique Agbor-Tarh
Holger Eidtmann
Ian Bradbury
Jeff Sperinde
John Winslow
Josep Lluis Parra
P304
P356
10.1158/1078-0432.CCR-14-1824
P407
P577
2014-12-02T00:00:00Z